Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21053992,total clearance,The total clearance value was low and increased with dose from 2.51 to 14.3 L/h.,Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),[l] / [h],2.51 to 14.3,706,DB08882,Linagliptin
,21053992,Renal excretion,Renal excretion of the unchanged parent compound increased with increasing plasma concentrations from 2.72% in the 0.5 mg dose group to 23.0% in the 10 mg dose group.,Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),%,2.72,707,DB08882,Linagliptin
,21053992,Renal excretion,Renal excretion of the unchanged parent compound increased with increasing plasma concentrations from 2.72% in the 0.5 mg dose group to 23.0% in the 10 mg dose group.,Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),%,23.0,708,DB08882,Linagliptin
,21053992,terminal elimination half-life,The terminal elimination half-life was comparable across dose groups (126-139 hours).,Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),h,126-139,709,DB08882,Linagliptin
,21053992,V(ss),"The model-derived estimates of the V(ss) and clearance of linagliptin not bound to DPP-4 were 402.2 L and 26.9 L/h, respectively.",Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),l,402.2,710,DB08882,Linagliptin
,21053992,clearance,"The model-derived estimates of the V(ss) and clearance of linagliptin not bound to DPP-4 were 402.2 L and 26.9 L/h, respectively.",Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),[l] / [h],26.9,711,DB08882,Linagliptin
,21053992,absolute bioavailability,The absolute bioavailability was estimated to be about 30% for the linagliptin 10 mg tablet.,Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),%,30,712,DB08882,Linagliptin
,21053992,absolute bioavailability,"By a modelling approach, the absolute bioavailability of the 10 mg linagliptin tablet was estimated to be about 30%.",Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053992/),%,30,713,DB08882,Linagliptin
,32996028,association rate constant (kon),"The association rate constant (kon) in plasma and tissues were estimated to be 0.943 and 0.00680 nM-1 h-1, respectively, and dissociation rate constant (koff), in plasma and tissues were estimated to be 0.0698 and 0.00880 h-1, respectively.",Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),1/[h·nM],0.943,4091,DB08882,Linagliptin
,32996028,association rate constant (kon),"The association rate constant (kon) in plasma and tissues were estimated to be 0.943 and 0.00680 nM-1 h-1, respectively, and dissociation rate constant (koff), in plasma and tissues were estimated to be 0.0698 and 0.00880 h-1, respectively.",Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),1/[h·nM],0.00680,4092,DB08882,Linagliptin
,32996028,dissociation rate constant (koff),"The association rate constant (kon) in plasma and tissues were estimated to be 0.943 and 0.00680 nM-1 h-1, respectively, and dissociation rate constant (koff), in plasma and tissues were estimated to be 0.0698 and 0.00880 h-1, respectively.",Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),1/[h],0.0698,4093,DB08882,Linagliptin
,32996028,dissociation rate constant (koff),"The association rate constant (kon) in plasma and tissues were estimated to be 0.943 and 0.00680 nM-1 h-1, respectively, and dissociation rate constant (koff), in plasma and tissues were estimated to be 0.0698 and 0.00880 h-1, respectively.",Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),1/[h],0.00880,4094,DB08882,Linagliptin
,32996028,Kd,The binding affinity of linagliptin to DPP-4 (Kd) was predicted to be higher in plasma (0.0740 nM) than that in tissue (1.29 nM).,Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),nM,0.0740,4095,DB08882,Linagliptin
,32996028,Kd,The binding affinity of linagliptin to DPP-4 (Kd) was predicted to be higher in plasma (0.0740 nM) than that in tissue (1.29 nM).,Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32996028/),nM,1.29,4096,DB08882,Linagliptin
,20086031,area under the curve 0-24 h,"The exposure (area under the curve 0-24 h) to the parent compound in plasma accounted for 191 nM . h (p.o.) and 356 nM . h (i.v.), respectively.","The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086031/),h·nM,191,10200,DB08882,Linagliptin
,20086031,area under the curve 0-24 h,"The exposure (area under the curve 0-24 h) to the parent compound in plasma accounted for 191 nM . h (p.o.) and 356 nM . h (i.v.), respectively.","The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086031/),h·nM,356,10201,DB08882,Linagliptin
,24154935,inhibition,"Median dipeptidyl peptidase-4 inhibition over a 24-h interval at steady state was 85.9% with linagliptin 5 mg once-daily and 86.5% with 2.5 mg twice-daily, and median dipeptidyl peptidase-4 inhibition values were approximately 80.0% at trough.",Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154935/),,80,11290,DB08882,Linagliptin
<,21672124,Renal excretion,Renal excretion of unchanged linagliptin was <7% in all groups.,Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672124/),%,7,14469,DB08882,Linagliptin
,21672124,accumulation half-life,The accumulation half-life of linagliptin ranged from 14-15 h in subjects with normal renal function to 18 h in severe renal impairment.,Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672124/),h,14-15,14470,DB08882,Linagliptin
,21672124,accumulation half-life,The accumulation half-life of linagliptin ranged from 14-15 h in subjects with normal renal function to 18 h in severe renal impairment.,Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672124/),h,18,14471,DB08882,Linagliptin
,26426933,IC50,"The most potent inhibitor is (R)-40 (IC50 = 23.5 nm, F = 74.67%, T1/2 = 4 h), which exhibited moderate antihyperglycemic activity as compared to the standard antidiabetic drug Linagliptin in OGTT.","Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26426933/),nm,23.5,15014,DB08882,Linagliptin
,26426933,F,"The most potent inhibitor is (R)-40 (IC50 = 23.5 nm, F = 74.67%, T1/2 = 4 h), which exhibited moderate antihyperglycemic activity as compared to the standard antidiabetic drug Linagliptin in OGTT.","Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26426933/),%,74.67,15015,DB08882,Linagliptin
,26426933,T1/2,"The most potent inhibitor is (R)-40 (IC50 = 23.5 nm, F = 74.67%, T1/2 = 4 h), which exhibited moderate antihyperglycemic activity as compared to the standard antidiabetic drug Linagliptin in OGTT.","Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26426933/),h,4,15016,DB08882,Linagliptin
,24755124,peak plasma concentrations,"After food intake, peak plasma concentrations of linagliptin were slightly lowered (from 4.99 to 4.56 nmol L⁻¹), but the 90% confidence interval (CI) of the geometric mean test/reference ratio was still located within the generally applied bioequivalence acceptance limits of 80 - 125%.",Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),l⁻¹·nM,4.99,19023,DB08882,Linagliptin
,24755124,peak plasma concentrations,"After food intake, peak plasma concentrations of linagliptin were slightly lowered (from 4.99 to 4.56 nmol L⁻¹), but the 90% confidence interval (CI) of the geometric mean test/reference ratio was still located within the generally applied bioequivalence acceptance limits of 80 - 125%.",Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),l⁻¹·nM,4.56,19024,DB08882,Linagliptin
,24755124,tmax,Administration with food reduced the rate of absorption of metformin indicated by a prolongation in median tmax (from 2 to 4 hours) and a decrease in Cmax by ~ 18%.,Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),h,2,19025,DB08882,Linagliptin
,24755124,tmax,Administration with food reduced the rate of absorption of metformin indicated by a prolongation in median tmax (from 2 to 4 hours) and a decrease in Cmax by ~ 18%.,Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755124/),h,4,19026,DB08882,Linagliptin
,31256062,oral bioavailability,The oral bioavailability of linagliptin is low (29.5%) due to its first pass metabolism in the intestine and liver.,Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256062/),%,29.5,34852,DB08882,Linagliptin
,21867423,dissociation half-life,Dilution assay indicated a long dissociation half-life (730 min) relative to DPPIV inhibitor vildagliptin.,Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21867423/),min,730,53845,DB08882,Linagliptin
,20637971,T(max),"T(max) ranged from 1.50 to 6.00 hours, and elimination t((1/2)) ranged from 96.9 to 175.0 hours.","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),h,1.50 to 6.00,67372,DB08882,Linagliptin
,20637971,elimination t((1/2)),"T(max) ranged from 1.50 to 6.00 hours, and elimination t((1/2)) ranged from 96.9 to 175.0 hours.","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),h,96.9 to 175.0,67373,DB08882,Linagliptin
,20637971,Total CL,"Total CL increased with increasing dose (from 140 mL/min in the 1-mg group to 314 mL/min in the 10-mg group), as did apparent V(d) (from 1260 to 3060 L with doses up to 10 mg).","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),[ml] / [min],140,67374,DB08882,Linagliptin
,20637971,Total CL,"Total CL increased with increasing dose (from 140 mL/min in the 1-mg group to 314 mL/min in the 10-mg group), as did apparent V(d) (from 1260 to 3060 L with doses up to 10 mg).","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),[ml] / [min],314,67375,DB08882,Linagliptin
,20637971,apparent V(d),"Total CL increased with increasing dose (from 140 mL/min in the 1-mg group to 314 mL/min in the 10-mg group), as did apparent V(d) (from 1260 to 3060 L with doses up to 10 mg).","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),l,126,67376,DB08882,Linagliptin
,20637971,apparent V(d),"Total CL increased with increasing dose (from 140 mL/min in the 1-mg group to 314 mL/min in the 10-mg group), as did apparent V(d) (from 1260 to 3060 L with doses up to 10 mg).","Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),l,306,67377,DB08882,Linagliptin
,20637971,accumulation t((1/2)),The accumulation t((1/2)) ranged from approximately 10 to 15 hours.,"Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),h,10 to 15,67378,DB08882,Linagliptin
<,20637971,accumulation ratio,The accumulation ratio with multiple dosing was <1.5 and decreased with increasing dose (approximately 1.2 in the 10-mg dose).,"Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),,1.5,67379,DB08882,Linagliptin
<,20637971,accumulation ratio,The accumulation ratio with multiple dosing was <1.5 and decreased with increasing dose (approximately 1.2 in the 10-mg dose).,"Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637971/),,1.2,67380,DB08882,Linagliptin
,27353348,flow rate,Both LNG and PIN were separated on a Zorbax Eclipse XDB C18 column kept at ambient temperature using as mobile phase a combination of 75% methanol: 25% formic acid 0.1% pH 4.1 at a flow rate of 1.0 mL min-1.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ml] / [min],1.0,71019,DB08882,Linagliptin
,27353348,limit of quantification (LOQ),The limit of quantification (LOQ) was found to be 5 ng mL-1 based on 100 µL of plasma.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],5,71020,DB08882,Linagliptin
>,27353348,extraction recovery (R%),The extraction recovery (R%) was >83%.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),%,83,71021,DB08882,Linagliptin
,27353348,maximum concentration (Cmax),"The maximum concentration (Cmax) and the area under the plasma concentration-time curve (AUC0-72) were 927.5 ± 23.9 and 18,285.02 ± 605.76 ng mL-1, respectively.",A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],927.5,71022,DB08882,Linagliptin
,27353348,area under the plasma concentration-time curve (AUC0-72),"The maximum concentration (Cmax) and the area under the plasma concentration-time curve (AUC0-72) were 927.5 ± 23.9 and 18,285.02 ± 605.76 ng mL-1, respectively.",A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],"18,285.02",71023,DB08882,Linagliptin
,25233638,total run time,A chromatographic total run time of 4.4 min was achieved.,[Determination of yogliptin and its metabolite in Wistar rat plasma by liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233638/),min,4.4,89334,DB08882,Linagliptin
≤,22242621,renal excretion,Accumulation based on AUC or C(max) and renal excretion of unchanged linagliptin (≤ 7%) were comparable across groups.,Pharmacokinetics of linagliptin in subjects with hepatic impairment. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242621/),,7,94792,DB08882,Linagliptin
<,31336309,IC50,"After systematic structure-activity relationship (SAR) study around benzoic acid moieties, 5 novel DPP-4 inhibitors with low picomolar potency range (IC50 < 1 nM) and excellent selectivity against various DPP-4 homologues were identified, in which the best one, compound 2f, with the IC50 value of 0.1 nM for DPP-4, showed 22-fold improvement in inhibitory activity compared to lead compound uracil 1, its activity was 45-fold more potent than alogliptin.","Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336309/),nM,1,98020,DB08882,Linagliptin
,31336309,IC50,"After systematic structure-activity relationship (SAR) study around benzoic acid moieties, 5 novel DPP-4 inhibitors with low picomolar potency range (IC50 < 1 nM) and excellent selectivity against various DPP-4 homologues were identified, in which the best one, compound 2f, with the IC50 value of 0.1 nM for DPP-4, showed 22-fold improvement in inhibitory activity compared to lead compound uracil 1, its activity was 45-fold more potent than alogliptin.","Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336309/),nM,0.1,98021,DB08882,Linagliptin
,21543033,Eax,"The corresponding Eax values for both INR and PT were slightly increased after co-administration of linagliptin and warfarin compared with warfarin alone, being 104.3 (85.2 - 127.6) and 15.1 (94.3 -140.6), respectively, reflecting the higher variability of these endpoints.",Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543033/),,104.3,112854,DB08882,Linagliptin
,21543033,Eax,"The corresponding Eax values for both INR and PT were slightly increased after co-administration of linagliptin and warfarin compared with warfarin alone, being 104.3 (85.2 - 127.6) and 15.1 (94.3 -140.6), respectively, reflecting the higher variability of these endpoints.",Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543033/),,15.1,112855,DB08882,Linagliptin
,23411609,trough concentration,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],5.93,151078,DB08882,Linagliptin
,23411609,trough concentration,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],6.07,151079,DB08882,Linagliptin
,23411609,trough concentration,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],7.34,151080,DB08882,Linagliptin
,23411609,trough concentration,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],8.13,151081,DB08882,Linagliptin
,23411609,concentrations,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],6.07,151082,DB08882,Linagliptin
,23411609,concentrations,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],7.34,151083,DB08882,Linagliptin
,23411609,concentrations,"In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively.",Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411609/),[nM] / [l],8.13,151084,DB08882,Linagliptin
,23073142,time to maximum concentration,Linagliptin was rapidly absorbed; median time to maximum concentration was 1.75 h for single dose and 1.5 h at steady-state.,Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),h,1.75,157511,DB08882,Linagliptin
,23073142,time to maximum concentration,Linagliptin was rapidly absorbed; median time to maximum concentration was 1.75 h for single dose and 1.5 h at steady-state.,Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),h,1.5,157512,DB08882,Linagliptin
,23073142,Maximum plasma drug concentration (Cmax),"Maximum plasma drug concentration (Cmax) after single dose was 4.9 ng/ml (10.4 nM), with a geometric coefficient of variation (gCV) 46%.",Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),[ng] / [ml],4.9,157513,DB08882,Linagliptin
,23073142,area under the plasma concentrationtime curve (AUC),"The corresponding geometric mean area under the plasma concentrationtime curve (AUC) was 71 ng×h ml-1 (150 nmol×h l-1, gCV 25%).",Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),[h·ng] / [ml],71,157514,DB08882,Linagliptin
,23073142,area under the plasma concentrationtime curve (AUC),"The corresponding geometric mean area under the plasma concentrationtime curve (AUC) was 71 ng×h ml-1 (150 nmol×h l-1, gCV 25%).",Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),[h·nM] / [l],150,157515,DB08882,Linagliptin
,23073142,Cmax,"At steady-state, Cmax and AUC were 6.7 ng/ml (14.1 nM, gCV 49%) and 96 nmol×h l-1 (204 nmol×h l-1, gCV 25%).",Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),[ng] / [ml],6.7,157516,DB08882,Linagliptin
,23073142,AUC,"At steady-state, Cmax and AUC were 6.7 ng/ml (14.1 nM, gCV 49%) and 96 nmol×h l-1 (204 nmol×h l-1, gCV 25%).",Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),[h·nM] / [l],96,157517,DB08882,Linagliptin
,23073142,accumulation half-life,An accumulation half-life of ~ 11.5 h (gCV 46.9%) was calculated.,Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),h,11.5,157518,DB08882,Linagliptin
<,23073142,Renal excretion,Renal excretion of linagliptin was low and < 8% of administered dose at steady-state (< 2% at Day 1).,Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),%,8,157519,DB08882,Linagliptin
<,23073142,Renal excretion,Renal excretion of linagliptin was low and < 8% of administered dose at steady-state (< 2% at Day 1).,Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073142/),%,2,157520,DB08882,Linagliptin
,21306414,MCfB,"The placebo-corrected MCfB of QT(c) I was -1.1 (90% CI -2.7, 0.5) ms and -2.5 (-4.1, -0.9) ms for linagliptin 5 mg and 100 mg, respectively, thus within the non-inferiority margin of 10 ms according to ICH E14.",The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306414/),ms,2.5,169257,DB08882,Linagliptin
,21306414,MCfB,"Assay sensitivity was confirmed by a placebo-corrected MCfB of QT(c) I with moxifloxacin of 6.9 (90% CI 5.4, 8.5) ms.",The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306414/),ms,6.9,169258,DB08882,Linagliptin
,32804301,oral bioavailability,One of the major disadvantages of LGP is its low oral bioavailability (29.5%) due to first-pass metabolism and P-gp efflux.,Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),%,29.5,174263,DB08882,Linagliptin
,32804301,particle,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),nm,225.96,174264,DB08882,Linagliptin
,32804301,polydispersity index,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),mv,0.180,174265,DB08882,Linagliptin
,32804301,zeta potential,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),mv,0.180,174266,DB08882,Linagliptin
,32804301,%EE,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),mv,-,174267,DB08882,Linagliptin
,32804301,%EE,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),mv,5.4,174268,DB08882,Linagliptin
,32804301,%EE,"The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively.",Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),%,73.8,174269,DB08882,Linagliptin
,32804301,relative bioavailability,LGP-SLNs exhibited relative bioavailability of 300% and better reduction in glucose levels in comparison with LGP-SOL in rats.,Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32804301/),%,300,174270,DB08882,Linagliptin
,21723606,terminal half-life,"The terminal half-life was long (223-260 hours) but did not reflect the accumulation half-life (10.0-38.5 hours), resulting in a moderate accumulation ratio of <2.9 that decreased with increasing dose.","Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723606/),h,223-260,201220,DB08882,Linagliptin
,21723606,accumulation half-life,"The terminal half-life was long (223-260 hours) but did not reflect the accumulation half-life (10.0-38.5 hours), resulting in a moderate accumulation ratio of <2.9 that decreased with increasing dose.","Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723606/),h,10.0-38.5,201221,DB08882,Linagliptin
<,21723606,accumulation ratio,"The terminal half-life was long (223-260 hours) but did not reflect the accumulation half-life (10.0-38.5 hours), resulting in a moderate accumulation ratio of <2.9 that decreased with increasing dose.","Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723606/),,2.9,201222,DB08882,Linagliptin
up to,18812608,terminal half-life,The geometric mean terminal half-life was up to 184 hours.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812608/),h,184,201300,DB08882,Linagliptin
,18812608,time to achieve maximum inhibition,The time to achieve maximum inhibition shifted with increasing doses from 3 hours (2.5 mg) to <0.7 hours (> or =200 mg).,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812608/),h,3,201301,DB08882,Linagliptin
<,18812608,time to achieve maximum inhibition,The time to achieve maximum inhibition shifted with increasing doses from 3 hours (2.5 mg) to <0.7 hours (> or =200 mg).,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812608/),h,0.7,201302,DB08882,Linagliptin
,19476474,Accumulation half-life,"Accumulation half-life was short (8.6-23.9 h), resulting in rapid attainment of steady state (2-5 days) and little accumulation (range: 1.18-2.03).","Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476474/),h,8.6-23.9,230702,DB08882,Linagliptin
,19476474,terminal half-life,The long terminal half-life (113-131 h) led to a sustained inhibition of DPP-4 activity.,"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476474/),h,113-131,230703,DB08882,Linagliptin
below,19476474,Renal excretion,Renal excretion was below 1% on day 1 in all dose groups.,"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476474/),%,1,230704,DB08882,Linagliptin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,473.24,230705,DB08882,Linagliptin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,419.94,230706,DB08882,Linagliptin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,130.14,230707,DB08882,Linagliptin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,60.18,230708,DB08882,Linagliptin
,30312887,m/,"The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively.",A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30312887/),,340.27,230709,DB08882,Linagliptin
,20160157,CL/F,"Although unbound linagliptin is cleared efficiently (CL/F 220 L/h), the concentration-dependent binding is responsible for the long terminal half-life (approximatelly 120 hours) of linagliptin and its nonlinear pharmacokinetics.",Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160157/),[l] / [h],220,231390,DB08882,Linagliptin
,20160157,terminal half-life,"Although unbound linagliptin is cleared efficiently (CL/F 220 L/h), the concentration-dependent binding is responsible for the long terminal half-life (approximatelly 120 hours) of linagliptin and its nonlinear pharmacokinetics.",Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160157/),h,120,231391,DB08882,Linagliptin
,23994324,IC50,"Although it did not exhibit the desired activity (IC50=0.2 μM), compound 11a acts as a lead compound, which triggered a resulting structural optimization and the formation of compound 11m.",Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23994324/),μM,0.2,249324,DB08882,Linagliptin
,23994324,IC50,A novel series of potent DPP-IV inhibitors represented by compound 11m (IC50=0.4 nM) was ultimately obtained with a robust pharmacokinetic profile and superior in vitro and in vivo efficacy compared to Alogliptin.,Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23994324/),nM,0.4,249325,DB08882,Linagliptin
,23331248,AUC,"Linagliptin geometric mean AUC was 194 nmol l(-1) h (geometric coefficient of variation, 26%), with a Cmax of 16.4 nmol l(-1) (41%).",Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331248/),[h·nM] / [l],194,258643,DB08882,Linagliptin
,23331248,Cmax,"Linagliptin geometric mean AUC was 194 nmol l(-1) h (geometric coefficient of variation, 26%), with a Cmax of 16.4 nmol l(-1) (41%).",Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331248/),[nM] / [l],16.4,258644,DB08882,Linagliptin
,23331248,Urinary excretion,"Urinary excretion was low (0.5% and 4.4% of the dose excreted over 24 h, days 1 and 7).",Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331248/),%,0.5,258645,DB08882,Linagliptin
,23331248,Urinary excretion,"Urinary excretion was low (0.5% and 4.4% of the dose excreted over 24 h, days 1 and 7).",Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331248/),%,4.4,258646,DB08882,Linagliptin
,22568694,steady-state C(max),"With the therapeutic dose, steady-state C(max) (11-12 nmol/L) and AUC (∼150 nmol · h/L) are approximately 1.3-fold greater than after a single dose, indicating little drug accumulation with repeat dosing.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[nM] / [l],11-12,263484,DB08882,Linagliptin
,22568694,AUC,"With the therapeutic dose, steady-state C(max) (11-12 nmol/L) and AUC (∼150 nmol · h/L) are approximately 1.3-fold greater than after a single dose, indicating little drug accumulation with repeat dosing.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[h·nM] / [l],∼150,263485,DB08882,Linagliptin
,22568694,oral bioavailability,The oral bioavailability of linagliptin estimated with this model is approximately 30%.,Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),%,30,263486,DB08882,Linagliptin
>,22568694,terminal half-life,"Linagliptin has a long terminal half-life (>100 hours); however, its accumulation half-life is much shorter (approximately 10 hours), accounting for the rapid attainment of steady state.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),h,100,263487,DB08882,Linagliptin
,22568694,accumulation half-life,"Linagliptin has a long terminal half-life (>100 hours); however, its accumulation half-life is much shorter (approximately 10 hours), accounting for the rapid attainment of steady state.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),h,10,263488,DB08882,Linagliptin
,22568694,inhibition constant,"Linagliptin potently inhibits DPP-4 (inhibition constant 1 nmol/L), and trough drug concentrations achieved with therapeutic dosing inhibit >80% of plasma DPP-4 activity, the threshold associated with maximal antihyperglycaemic effects in animal models.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[nM] / [l],1,263489,DB08882,Linagliptin
,24996141,IC50,"The most promising compound 2h (IC50 = 0.31 nM) exhibited 8.5-fold and 2.5-fold more potent activity than that of alogliptin (IC50 = 2.63 nM) and linagliptin (IC50 = 0.77 nM), respectively.",Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24996141/),nM,0.31,268601,DB08882,Linagliptin
,24996141,IC50,"The most promising compound 2h (IC50 = 0.31 nM) exhibited 8.5-fold and 2.5-fold more potent activity than that of alogliptin (IC50 = 2.63 nM) and linagliptin (IC50 = 0.77 nM), respectively.",Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24996141/),nM,2.63,268602,DB08882,Linagliptin
,24996141,IC50,"The most promising compound 2h (IC50 = 0.31 nM) exhibited 8.5-fold and 2.5-fold more potent activity than that of alogliptin (IC50 = 2.63 nM) and linagliptin (IC50 = 0.77 nM), respectively.",Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24996141/),nM,0.77,268603,DB08882,Linagliptin
